Synonyms: compound 18 [PMID: 36624931] | MK8189
Compound class:
Synthetic organic
Comment: MK-8189 is a selective inhibitor of PDE10A that was designed to normalise dysfunctional striatal signalling activity, as a mechanism to treat schizophrenia [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
MK-8189 has been advnced to clinical evaluation in patients with schizophrenia or Alzheimer's disease. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05227118 | MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017) | Phase 1 Interventional | Merck Sharp & Dohme LLC | ||
NCT04624243 | Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) | Phase 2 Interventional | Merck Sharp & Dohme LLC | ||
NCT03055338 | An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005) | Phase 2 Interventional | Merck Sharp & Dohme LLC |